Co-Authors
This is a "connection" page, showing publications co-authored by SAMIR HANASH and AYUMU TAGUCHI.
Connection Strength
7.573
-
A Promising CPS1 Inhibitor Keeping Ammonia from Fueling Cancer. Cell Chem Biol. 2020 03 19; 27(3):253-254.
Score: 0.719
-
Failure to Disclose Potential Conflict of Interest-Letter of Explanation. JAMA Oncol. 2019 12 01; 5(12):1811.
Score: 0.704
-
MAPRE1 as a plasma biomarker for early-stage colorectal cancer and adenomas. Cancer Prev Res (Phila). 2015 Nov; 8(11):1112-9.
Score: 0.525
-
Mouse to human blood-based cancer biomarker discovery strategies. Cold Spring Harb Protoc. 2014 Feb 01; 2014(2):144-9.
Score: 0.470
-
Unleashing the power of proteomics to develop blood-based cancer markers. Clin Chem. 2013 Jan; 59(1):119-26.
Score: 0.430
-
Integration of proteomics into systems biology of cancer. Wiley Interdiscip Rev Syst Biol Med. 2012 Jul-Aug; 4(4):327-37.
Score: 0.412
-
Application of proteomics to cancer early detection. Cancer J. 2011 Nov-Dec; 17(6):423-8.
Score: 0.402
-
The grand challenge to decipher the cancer proteome. Nat Rev Cancer. 2010 09; 10(9):652-60.
Score: 0.371
-
Circulating microRNA Panel for Prediction of Recurrence and Survival in Early-Stage Lung Adenocarcinoma. Int J Mol Sci. 2024 Feb 16; 25(4).
Score: 0.236
-
SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas. J Natl Cancer Inst. 2022 02 07; 114(2):290-301.
Score: 0.205
-
Identification of Blood-Based Biomarkers for the Prediction of the Response to Neoadjuvant Chemoradiation in Rectal Cancer. Cancers (Basel). 2021 Jul 20; 13(14).
Score: 0.197
-
A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. J Natl Cancer Inst. 2019 04 01; 111(4):372-379.
Score: 0.168
-
Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Nat Commun. 2019 01 16; 10(1):254.
Score: 0.166
-
Plasma-derived extracellular vesicle proteins as a source of biomarkers for lung adenocarcinoma. Oncotarget. 2017 Nov 10; 8(56):95466-95480.
Score: 0.151
-
MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway. Cancer Res. 2017 08 15; 77(16):4414-4425.
Score: 0.149
-
Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. J Natl Cancer Inst. 2017 04 01; 109(4).
Score: 0.146
-
Switching Roles of TGF-? in Cancer Development: Implications for Therapeutic Target and Biomarker Studies. J Clin Med. 2016 Nov 30; 5(12).
Score: 0.143
-
Deciphering the complexity of the cancer proteome for diagnostic applications. Expert Rev Mol Diagn. 2016; 16(4):399-405.
Score: 0.135
-
Serum Glycans as Risk Markers for Non-Small Cell Lung Cancer. Cancer Prev Res (Phila). 2016 Apr; 9(4):317-23.
Score: 0.135
-
Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B. J Clin Oncol. 2015 Nov 20; 33(33):3880-6.
Score: 0.131
-
Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. J Natl Cancer Inst. 2015 Aug; 107(8).
Score: 0.129
-
Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival. Cancer Res. 2015 May 01; 75(9):1789-800.
Score: 0.127
-
Proteomic signatures associated with p53 mutational status in lung adenocarcinoma. Proteomics. 2014 Dec; 14(23-24):2750-9.
Score: 0.124
-
A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes, expanding the repertoire of potential immunotherapeutic targets. Cancer Res. 2014 Sep 01; 74(17):4694-705.
Score: 0.121
-
Pro-surfactant protein B as a biomarker for lung cancer prediction. J Clin Oncol. 2013 Dec 20; 31(36):4536-43.
Score: 0.116
-
Circulating pro-surfactant protein B as a risk biomarker for lung cancer. Cancer Epidemiol Biomarkers Prev. 2013 Oct; 22(10):1756-61.
Score: 0.113
-
Comprehensive proteomic profiling of aldehyde dehydrogenases in lung adenocarcinoma cell lines. Int J Proteomics. 2011; 2011:145010.
Score: 0.100
-
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell. 2011 Sep 13; 20(3):289-99.
Score: 0.100
-
A Comprehensive Search of Non-Canonical Proteins in Non-Small Cell Lung Cancer and Their Impact on the Immune Response. Int J Mol Sci. 2022 Aug 11; 23(16).
Score: 0.053
-
Mutational Activation of the NRF2 Pathway Upregulates Kynureninase Resulting in Tumor Immunosuppression and Poor Outcome in Lung Adenocarcinoma. Cancers (Basel). 2022 May 21; 14(10).
Score: 0.052
-
Novel urinary protein biomarker panel for early diagnosis of gastric cancer. Br J Cancer. 2020 11; 123(11):1656-1664.
Score: 0.046
-
The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. Gastroenterology. 2020 12; 159(6):2146-2162.e33.
Score: 0.046
-
Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer. Gut. 2020 10; 69(10):1818-1831.
Score: 0.044
-
Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature. 2019 04; 568(7752):410-414.
Score: 0.042
-
Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins. JAMA Oncol. 2018 10 01; 4(10):e182078.
Score: 0.041
-
HIV Infection and Circulating Levels of Prosurfactant Protein B and Surfactant Protein D. J Infect Dis. 2018 01 17; 217(3):413-417.
Score: 0.039
-
Role of CPS1 in Cell Growth, Metabolism and Prognosis in LKB1-Inactivated Lung Adenocarcinoma. J Natl Cancer Inst. 2017 03 01; 109(3):1-9.
Score: 0.036
-
A statistical method for detecting differentially expressed SNVs based on next-generation RNA-seq data. Biometrics. 2017 03; 73(1):42-51.
Score: 0.035
-
Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. Proc Natl Acad Sci U S A. 2016 Mar 15; 113(11):E1555-64.
Score: 0.034
-
Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. Mol Cell. 2016 Feb 18; 61(4):640.
Score: 0.034
-
Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. Mol Cell. 2016 Feb 18; 61(4):520-534.
Score: 0.034
-
Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry. Metabolites. 2015 Apr 09; 5(2):192-210.
Score: 0.032
-
CDKN2A/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small-cell lung cancer. J Thorac Oncol. 2013 Nov; 8(11):1378-88.
Score: 0.029
-
Enrichment strategies in glycomics-based lung cancer biomarker development. Proteomics Clin Appl. 2013 Oct; 7(9-10):664-76.
Score: 0.028
-
Integrated mass spectrometry-based analysis of plasma glycoproteins and their glycan modifications. Nat Protoc. 2011 Mar; 6(3):253-69.
Score: 0.024